azomycin has been researched along with bedaquiline in 152 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (3.95) | 29.6817 |
| 2010's | 103 (67.76) | 24.3611 |
| 2020's | 43 (28.29) | 2.80 |
| Authors | Studies |
|---|---|
| Andries, K; Chauffour, A; Jarlier, V; Ji, B | 1 |
| Chauffour, A; Jarlier, V; Ji, B; Lefrançois, S; Robert, J; Truffot, C | 1 |
| Aly, S; Andries, K; Basaraba, RJ; Cantarero, L; Ehlers, S; Hoff, D; Lenaerts, AJ; Orme, IM | 1 |
| Spigelman, MK | 1 |
| Nau, JY | 2 |
| Mancera, RL; Rivers, EC | 1 |
| Nuermberger, EL; Spigelman, MK; Yew, WW | 1 |
| Ginsberg, A | 1 |
| Andries, K; Li, SY; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Tasneen, R; Taylor, D; Williams, KN | 1 |
| Campbell, S; Jakubiec, W; Ladutko, L; Miller, PF; Mitton-Fry, M; Paige, D; Silvia, A; Wallis, RS | 1 |
| Becker, P; Dawson, R; Diacon, AH; Donald, PR; Everitt, D; Mendel, CM; Spigelman, MK; Symons, G; van Niekerk, C; Venter, A; von Groote-Bidlingmaier, F; Winter, H | 1 |
| Cole, ST; Hartkoorn, RC; Lechartier, B | 1 |
| Schaberg, T | 1 |
| Boechat, N; Branco, FS; Pinto, AC | 1 |
| Elamin, AA; Singh, M; Stehr, M | 1 |
| Balasegaram, M; Brigden, G; du Cros, P; Horsburgh, CR; Hughes, J; McIlleron, H; Mitnick, CD; Nuermberger, E; Nyang'wa, BT; Phillips, PP; Rich, M; Varaine, F | 1 |
| Burki, T | 2 |
| Jeong, BH; Koh, WJ; Kwon, YS | 1 |
| Amoabeng, O; Mdluli, KE; Minkowski, A; Nuermberger, EL; Tasneen, R; Upton, AM; Williams, K | 1 |
| Chang, KC; Heyckendorf, J; Lange, C; Olaru, ID; von Groote-Bidlingmaier, F; Yew, WW | 1 |
| Centis, R; D'ambrosio, L; Migliori, GB; Sotgiu, G | 1 |
| Burger, DA; Dawson, R; Diacon, AH; Donald, PR; Everitt, D; Hutchings, J; Mendel, CM; Schall, R; Symons, G; van Niekerk, C; Venter, A; von Groote-Bidlingmaier, F | 1 |
| Abubakar, I; Brown, NM; Burman, WJ; Ellington, MJ; Feuerriegel, S; Ismail, NA; Javid, B; Köser, CU; Liddell, K; Moore, D; Niemann, S; Peacock, SJ; Török, ME | 1 |
| Cox, H; Daniels, C; Furin, J; Lessem, E; McKenna, L; Mitnick, CD; Mosidi, T; Reed, C; Seaworth, B; Stillo, J; Tisile, P; von Delft, D | 1 |
| Bloemberg, GV; Böttger, EC; Hömke, R; Keller, PM; Ritter, C; Valsesia, G | 1 |
| Ballinger, E; Glasheen, J; Gold, B; Ling, Y; Nathan, C; Quezada, LL; Roberts, J; Somersan-Karakaya, S; Warren, JD; Warrier, T | 1 |
| Bianchini, S; Blasi, F; Esposito, S | 1 |
| Caminero, JA; Scardigli, A | 1 |
| Cox, H; Furin, J; Lessem, E; Mason, L; Reed, C; Seaworth, B | 1 |
| Centis, R; D'Ambrosio, L; Migliori, GB; Pontali, E; Sotgiu, G; Spanevello, A | 1 |
| Diel, R; Gibbert, J; Wirth, D; Wolfson, LJ | 1 |
| Betoudji, F; Converse, PJ; Dartois, V; Li, SY; Mdluli, KE; Mendel, CM; Nuermberger, EL; Tasneen, R; Tyagi, S; Williams, K; Yang, T | 1 |
| Chopra, S; Dasgupta, A; De Groote, MA; Soni, I | 1 |
| Bloemberg, GV; Borrell, S; Böttger, EC; Coscolla, M; Feldmann, J; Gagneux, S; Hömke, R; Keller, PM; Latshang, T; Ritter, C; Rothe, T; Schulthess, B; Stucki, D; Stuckia, D; Trauner, A | 1 |
| Brigden, G; du Cros, P; Wong, S | 1 |
| Bastard, M; Bonnet, M; du Cros, P; Hayrapetyan, A; Hewison, C; Khamraev, A; Khurkhumal, S; Kimenye, K; Sanchez-Padilla, E; Telnov, A; Themba, D; Varaine, F | 1 |
| Dawson, A; Silva, DS; Upshur, RE | 1 |
| Beckert, P; Hoffmann, H; Hofmann-Thiel, S; Jaton, K; Keller, PM; Kohl, TA; Merker, M; Nedialkova, L; Niemann, S; Rothe, T; Sahalchyk, E | 1 |
| Brigden, G; Furin, J; Lessem, E; Lynch, S; Rich, M; Vaughan, L | 1 |
| Ben Amor, Y; Sullivan, T | 1 |
| Centis, R; D'Ambrosio, L; Enwerem, M; Lingtsang, RD; Migliori, GB; Sadutshang, TD; Tadolini, M; Tiberi, S | 2 |
| Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; Thee, S; van der Laan, L | 1 |
| Byun, JH; Kang, HR; Lee, EK; Park, JA; Shin, JY | 1 |
| Baudin, E; Cellamare, M; Mitnick, CD; Trippa, L; Ventz, S | 1 |
| Dedicoat, M | 1 |
| Akkerman, OW; Alffenaar, JC; Anthony, RM; Cobelens, FG; Grobusch, MP; Heysell, S; Tiberi, S; Van Soolingen, D | 1 |
| Wallis, RS | 1 |
| Centis, R; D'Ambrosio, L; Fuentes, Z; Migliori, GB; Sotgiu, G; Tiberi, S; Zumla, A | 1 |
| Gao, F; Hu, M; Zheng, C | 1 |
| Cooke, G; Fortunak, J; Gotham, D; Hill, A; Khoo, S; Nytko, FE; Pozniak, A | 1 |
| Centis, R; D'Ambrosio, L; Esposito, S; Migliori, GB; Pontali, E; Sotgiu, G; Tadolini, M; Tiberi, S | 1 |
| Cohen, J | 1 |
| Sharma, DC | 1 |
| Brzezinski, A; Milstein, M; Mitnick, CD; Varaine, F | 1 |
| Mendel, C; Murray, S; Spigelman, M | 1 |
| Dass, R; Hettle, R; Wirth, D | 1 |
| Converse, PJ; Li, SY; Mdluli, K; Nuermberger, EL; Soni, H; Tasneen, R; Tyagi, S | 1 |
| Dong, L; Fu, Y; Huang, H; Huo, F; Jing, W; Li, Y; Ma, Y; Pang, Y; Zhao, L; Zong, Z | 1 |
| Akkerman, O; Alffenaar, JW; Amale, R; Centis, R; D'Ambrosio, L; Ganatra, S; Maryandyshev, A; Migliori, GB; Mullerpattan, J; Pontali, E; Sadutshang, TD; Sotgiu, G; Tiberi, S; Topgyal, S; Udwadia, ZF | 1 |
| Jo, KW; Nam, GB; Shim, TS; Yoon, HY | 1 |
| Kabra, SK; Lodha, R; Mukherjee, A | 1 |
| Chang, KC; Cox, H; Dheda, K; Esmail, A; Lange, C; Wasserman, S | 1 |
| Cox, V; Furin, J; Lessem, E | 1 |
| Dowdy, D; Merritt, MW; Taylor, H; von Delft, A; Zwerling, A | 1 |
| Cox, H; Cox, V; Ditiu, L; Furin, J; Garcia-Prats, A; Koenig, S; Lessem, E; Nathavitharana, R; Reuter, A; Seddon, JA; Stillo, J; Tisile, P; von Delft, A; von Delft, D | 1 |
| Aarti, C; Barbabosa-Pliego, A; Khusro, A; Salem, AZM | 1 |
| Cox, V; Furin, J | 1 |
| Barkane, L; Caumes, E; Fréchet-Jachym, M; Guglielmetti, L; Kuksa, L; Le Dû, D; Marigot-Outtandy, D; Robert, J; Veziris, N; Yazdanpanah, Y | 1 |
| Akkerman, OW; Alffenaar, JW; Bolhuis, MS; de Lange, WCM; de Vries, G; de Zwaan, R; Dedicoat, M; Frijlink, HW; Gajraj, R; Grasmeijer, F; Hagedoorn, P; Kerstjens, HAM; Smith, G; van der Werf, TS; van Soolingen, D | 1 |
| Migliori, GB; Tadolini, M; Tiberi, S | 1 |
| Cox, H; De Avezedo, V; Egazaryan, L; Ferlazzo, G; Furin, J; Hewison, C; Hughes, J; Isaakidis, P; Jonckheere, S; Kalon, S; Khachatryan, N; Laxmeshwar, C; Mohr, E; Shroufi, A | 1 |
| Centis, R; D'Ambrosio, L; Migliori, GB; Pontali, E; Spanevello, A; Visca, D | 1 |
| Bujalska-Zadrozny, M; Pstragowski, M; Zbrzezna, M | 1 |
| Hun Choe, Y; Kim, CT; Kim, HR; Kim, TO; Ko, YC; Kwon, YS; Shin, HJ | 1 |
| Uplekar, M | 1 |
| Brigden, G; Cox, V; Crespo, RH; Furin, J; Lessem, E; Lynch, S; Rich, ML; Waning, B | 1 |
| Falzon, D; Halleux, CM; Jaramillo, E; Merle, C; Mirzayev, F; Olliaro, P; Weyer, K | 1 |
| Hauser, J; Jaramillo, E; Kuwana, R; Masini, T; Nhat Linh, N | 1 |
| Arbex, MA; D'Ambrosio, L; Dalcolmo, M; Duarte, R; Gaga, M; Migliori, GB; Munoz-Torrico, M; Rendon, A; Silva, DR; Tiberi, S; Visca, D; Zumla, A | 1 |
| Bothamley, G; Burman, M; Guglielmetti, L; Kunst, H; Lange, C; Tiberi, S; Togonidze, T; Wejse, C | 1 |
| Centis, R; D'Ambrosio, L; Migliori, GB; Pontali, E; Sotgiu, G; Spanevello, A; Tadolini, M; Tiberi, S; Visca, D | 1 |
| Borroni, E; Cirillo, DM; Crook, DW; Cugnata, F; Davies, TJ; Fowler, PW; Gibertoni Cruz, AL; Grazian, C; Hoosdally, SJ; Peto, TEA; Rancoita, PMV; Walker, TM | 1 |
| Flexner, C; Moss, DM; Owen, A; Podany, AT; Rajoli, RKR; Siccardi, M; Swindells, S | 1 |
| Choi, H; Kim, KJ; Lee, SH; Yang, JS | 1 |
| Perdigão, J; Portugal, I | 1 |
| Fan, Q; Ming, WK; Yip, WY; You, JHS | 1 |
| Gupta, R; Hafkin, J; Hittel, N; Martin, A | 1 |
| Li, Y; Sun, F; Zhang, W | 1 |
| Nair, SG; Patel, DB; Patel, HD; Rathwa, SK; Vasava, MS | 1 |
| Köser, CU; Kranzer, K; Maurer, FP | 1 |
| Laughon, BE; Lee, SFK; Lipman, M; McHugh, TD | 1 |
| Arora, VK; Chopra, KK | 1 |
| Khalid, UK; Mathuria, KK; Munjal, SK; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Verma, A; Vohra, V | 1 |
| Cox, H; Furin, J; Loveday, M; Reuter, A; Seddon, JA | 1 |
| Hoffmann, H; Hofmann-Thiel, S; Kranzer, K; Krieger, D; Merker, M; Niemann, S; Polsfuss, S; Rüssmann, H; Schönfeld, N | 1 |
| Akkerman, O; Al-Marzouqi, NH; Aleksa, A; Alffenaar, JW; Arias-Guillén, M; Belilovski, E; Bernal, E; Boeree, MJ; Borisov, SE; Bruchfeld, J; Cadiñanos Loidi, J; Cai, Q; Caminero, JA; Cebrian Gallardo, JJ; Centis, R; Codecasa, LR; D'Ambrosio, L; Dalcolmo, M; Danila, E; Dara, M; Davidavičienė, E; Davies Forsman, L; De Los Rios Jefe, J; Denholm, J; Duarte, R; Elamin, SE; Ferrarese, M; Filippov, A; Ganatra, S; Garcia, A; García-García, JM; Gayoso, R; Giraldo Montoya, AM; Gomez Rosso, RG; Gualano, G; Hoefsloot, W; Ilievska-Poposka, B; Jonsson, J; Khimova, E; Kuksa, L; Kunst, H; Laniado-Laborín, R; Li, Y; Magis-Escurra, C; Manfrin, V; Manga, S; Marchese, V; Martínez Robles, E; Maryandyshev, A; Matteelli, A; Migliori, GB; Mullerpattan, JB; Munoz-Torrico, M; Mustafa Hamdan, H; Nieto Marcos, M; Noordin, NM; Palmero, DJ; Palmieri, F; Payen, MC; Piubello, A; Pontali, E; Pontarelli, A; Quirós, S; Rendon, A; Skrahina, A; Šmite, A; Solovic, I; Sotgiu, G; Souleymane, MB; Spanevello, A; Stošić, M; Tadolini, M; Tiberi, S; Udwadia, ZF; van den Boom, M; Vescovo, M; Viggiani, P; Visca, D; Zhurkin, D; Zignol, M | 1 |
| De Azevedo, V; Ferlazzo, G; Hewison, C; Isaakidis, P; Mohr, E | 1 |
| Alffenaar, JC; Marais, BJ; Sintchenko, V | 1 |
| Daley, CL; Huh, HJ; Jeon, K; Jhun, BW; Kim, DH; Kim, SY; Koh, WJ; Kwon, OJ; Lee, NY; Moon, SM; Shin, SJ | 1 |
| Bethunaickan, R; Chandramohan, Y; Padmanaban, V; Ranganathan, UD; Swaminathan, S; Tripathy, S | 1 |
| Del Parigi, A; Everitt, D; Li, H; Li, M; Mendel, C; Nedelman, JR; Salinger, DH | 1 |
| Atwood, S; Bastard, M; Franke, MF; Hewison, C; Huerga, H; Khan, AJ; Khan, PY; Khan, U; Mitnick, CD; Rich, M; Seung, KJ; Varaine, F | 1 |
| Dheda, K; Dooley, KE; Furin, J; Gumbo, T; Maartens, G; Murray, M; Nardell, EA; Warren, RM | 1 |
| Cook-Scalise, S; Denkinger, CM; Dowdy, DW; Kendall, EA; Malhotra, S | 1 |
| Dheda, K; Esmail, A; Limberis, J; Olayanju, O | 1 |
| Avaliani, Z; Bablishvili, N; Barbakadze, K; Benkeser, D; Blumberg, HM; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA; Zhao, Y | 1 |
| Burger, DA; Conradie, A; Conradie, F; Crook, AM; Dawson, R; Diacon, AH; Everitt, DE; Haraka, F; Li, M; Mendel, CM; Ntinginya, NE; Okwera, A; Rassool, MS; Reither, K; Sebe, MA; Spigelman, M; Staples, S; Tweed, CD; van Niekerk, CH; Variava, E | 1 |
| Furin, J; McKenna, L | 1 |
| Gandhi, S; Shah, I; Shetty, NS | 1 |
| de Jong, BC; Decroo, T; Lynen, L; Piubello, A; Van Deun, A | 1 |
| Bateson, A; Conradie, F; Crook, AM; Diacon, AH; Egizi, E; Everitt, D; Howell, P; Hunt, R; Li, M; McHugh, TD; Mendel, CM; Moreira, J; Ngubane, N; Olugbosi, M; Spigelman, M; Timm, J; Van Niekerk, C; Wills, GH | 1 |
| Farhat, M; Kadura, S; King, N; Köser, CU; Nakhoul, M; Theron, G; Zhu, H | 1 |
| Jeon, D; Jo, KW; Kang, H; Shim, TS; Yim, JJ | 1 |
| Jeon, D; Jo, KW; Kang, H; Lee, HH; Shim, TS; Yim, JJ | 1 |
| Bigelow, KM; Chang, YS; Dooley, KE; Nuermberger, EL; Tasneen, R | 1 |
| Ader, F; Chiesi, S; Dominguez, J; Eimer, J; Guglielmetti, L; Masini, T; Robert, J; Varaine, F; Veziris, N | 1 |
| Aono, A; Kato, S; Mitarai, S; Ohta, K; Okumura, M; Takaki, A; Yoshiyama, T | 1 |
| Mathema, B; O'Donnell, M | 1 |
| Alikhanova, N; Barbova, A; Battaglia, S; Cabibbe, AM; Cirillo, DM; Dean, AS; Groenheit, R; Ismail, N; Meehan, CJ; Mostofa Kamal, SM; Niemann, S; Rigouts, L; Skrahina, A; Spitaleri, A; Tahseen, S; Utpatel, C; Zignol, M | 1 |
| Coutisson, S; Dalal, A; Das, M; Ferlazzo, G; Hossain, FN; Isaakidis, P; Kalon, S; Lachenal, N; Laxmeshwar, C; Mamnoon, F; Mansoor, H; Mathur, T; Meneguim, AC; Paryani, R; Ravi, S; Singh, P | 1 |
| Jeon, D; Kang, H; Kwon, YS; Shim, TS; Yim, JJ | 1 |
| Chopra, V; Gupta, A | 1 |
| Al-Shaer, MH; Alghamdi, WA; Barbakadze, K; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA | 1 |
| Auchynka, V; Charnysh, I; Hurevich, H; Katovich, D; Klimuk, D; Kumar, AMV; Sereda, Y; Setkina, S; Skrahin, A; Skrahina, A; Solodovnikova, V; Yedilbayev, A | 1 |
| Bax, HI; de Steenwinkel, JEM; Keutzer, L; Pieterman, ED; Simonsson, USH; van den Berg, S; van der Meijden, A; Wang, H; Zimmerman, MD | 1 |
| Comins, K; Conradie, F; Cramer, YS; De Los Rios, J; Diacon, AH; Donahue, K; Dooley, KE; Hafner, R; Lama, JR; Maartens, G; Moran, L; Morganroth, J; Rosenkranz, SL; Shenje, J; von Groote-Bidlingmaier, F | 1 |
| Acharya, S; Chavan, V; Das, M; Dhakulkar, S; Ferlazzo, G; Isaakidis, P; Iyer, A; Kalon, S; Mansoor, H; Meneguim, AC; Oswal, V; Ravi, S; Rebello, L; Shah, D; Sutar, N; Thakur, HP; Vengurlekar, D | 1 |
| Adenov, MM; Algozhin, YZ; Berikova, EA; Issayeva, AM; Maretbayeva, SM; Rakisheva, AS; Rich, ML; Seung, KJ; Stambekova, AT; Yedilbayev, A; Yeraliyeva, LT | 1 |
| Hwang, H; Jeon, D; Kang, H; Kwon, YS; Shim, TS; Yim, JJ | 1 |
| Acquah, R; Daniels, J; Furin, J; Loveday, M; Mohr-Holland, E; Mudaly, V; Reuter, A | 1 |
| Bao, J; Cheng, Q; Fan, J; He, P; He, W; Li, Y; Liu, C; Liu, D; Ma, A; Song, Y; Zhao, B; Zhao, Y | 1 |
| Campino, S; Clark, TG; Gomes, P; Gómez-González, PJ; Hibberd, ML; Napier, G; Perdigao, J; Phelan, JE; Portugal, I; Puyen, ZM; Santos-Lazaro, D; Viveiros, M | 1 |
| Avaliani, Z; Conradie, F; Cook-Scalise, S; Everitt, D; Garfin, AMC; Gomez, GB; Juneja, S; Kiria, N; Lomtadze, N; Malhotra, S; Ndjeka, N; Siapka, M; Spigelman, M; Vassall, A | 1 |
| Howell, P; Mvuna, N; Olugbosi, M; Upton, C | 1 |
| Almoslem, M; Drusano, GL; Duncanson, B; Kim, S; Louie, A; Myrick, J; Neely, M; Nole, J; Peloquin, CA; Scanga, CA; Schmidt, S; Yamada, W | 1 |
| Kumari, D; Perveen, S; Sharma, R; Singh, K | 1 |
| Cook-Scalise, S; Edo, P; Gebhard, A; Juneja, S; Kadyrov, A; Lawanson, A; Malhotra, S; Mambetova, E; Mulder, C; Pambudi, I; Rupert, S; Setiawan, E; Sohn, H; Sugiharto, J; Useni, S; van den Hof, S | 1 |
| Adenov, M; Adnan, S; Ahmed, S; Bastard, M; Coutisson, S; Danielyan, N; Franke, MF; Hewison, C; Huerga, H; Islam, S; Janmohamed, A; Kamene Kimenye, M; Karakozian, H; Khan, P; Khan, U; Kholikulov, B; Kirakosyan, O; Krisnanda, A; Kumsa, A; Lachenal, N; Leblanc, G; Lecca, L; Mamsa, S; Melikyan, N; Mitnick, CD; Nkuebe, M; Osso, E; Padayachee, S; Rich, ML; Seung, KJ; Thit, P; Varaine, F | 1 |
| Ahmed, S; Bastard, M; Franke, MF; Grium Tefera, D; Hewison, C; Holtzman, D; Huerga, H; Islam, S; Jacques Leblanc, G; Khan, PY; Khan, U; Kumsa, A; Lachenal, N; Leonovich, O; Mamsa, S; Manzur-Ul-Alam, M; Melikyan, N; Mitnick, CD; Myint, Z; Osso, E; Padayachee, S; Rafi Siddiqui, M; Rashitov, M; Rich, ML; Salahuddin, N; Salia, G; Sánchez, E; Serobyan, A; Seung, KJ; Varaine, F; Vetushko, D; Yeghiazaryan, L | 1 |
| Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD | 1 |
| De Los Rios, J; Diacon, AH; Dooley, KE; Karlsson, MO; Maartens, G; Shenje, J; Svensson, EM; Tanneau, L; Upton, CM; Wiesner, L | 1 |
| Cramer, YS; Diacon, AH; Dooley, KE; Karlsson, MO; Maartens, G; Morganroth, J; Rosenkranz, SL; Shenje, J; Svensson, EM; Tanneau, L; Upton, CM | 1 |
| Devaleenal, B; Mandal, S; Mattoo, S; Padmapriyadarsini, C; Parmar, M; Ponnuraja, C; Ramraj, B; Singla, R | 1 |
| Bagdasaryan, TR; Bateson, A; Borisov, S; Conradie, F; Crook, AM; Egizi, E; Everitt, D; Fabiane, SM; Foraida, S; Holsta, A; Howell, P; Hunt, R; Li, M; McHugh, TD; Mendel, CM; Mikiashvili, L; Ngubane, N; Olugbosi, M; Samoilova, A; Skornykova, S; Spigelman, M; Sun, E; Timm, J; Tudor, E; Tweed, CD; Variava, E; Wills, GH; Yablonskiy, P | 1 |
| Andersen, ÅB; Dahl, VN; Guglielmetti, L; Holmgaard, FB; Lillebaek, T; Wejse, C | 1 |
| Lyons, MA | 1 |
| Guo, T; Mehta, K; van der Graaf, PH; van Hasselt, JGC | 1 |
| Millard, J; Nimmo, C; O'Donnell, M; Rimmer, S | 1 |
| Bi, J; Li, L; Mi, K; Zhou, X; Zhu, H; Zhuang, Z | 1 |
37 review(s) available for azomycin and bedaquiline
| Article | Year |
|---|---|
New tuberculosis therapeutics: a growing pipeline.
Topics: Adamantane; Animals; Antitubercular Agents; Clinical Trials as Topic; Diamines; Diarylquinolines; Ethylenediamines; Fluoroquinolones; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Tuberculosis | 2007 |
New anti-tuberculosis drugs with novel mechanisms of action.
Topics: Adamantane; Animals; Antitubercular Agents; Diarylquinolines; Drug Design; Drug Resistance, Multiple, Bacterial; Ethylenediamines; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Quinolines; Structure-Activity Relationship; Tuberculosis, Pulmonary | 2008 |
Current development and future prospects in chemotherapy of tuberculosis.
Topics: Adamantane; Animals; Antitubercular Agents; Carbapenems; Clinical Trials as Topic; Diarylquinolines; Drug Delivery Systems; Ethylenediamines; Fluoroquinolones; Humans; Isonicotinic Acids; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Patient Compliance; Pyrroles; Quinolines; Rifamycins; Tuberculosis, Pulmonary | 2010 |
[Tuberculosis: new treatment options and updated recommendations].
Topics: Antitubercular Agents; Aza Compounds; Cross-Sectional Studies; Diagnosis, Differential; Diarylquinolines; Fluoroquinolones; Germany; Humans; Moxifloxacin; Nitroimidazoles; Oxazoles; Prognosis; Quinolines; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2013 |
An update on the chemistry and medicinal chemistry of novel antimycobacterial compounds.
Topics: Anti-HIV Agents; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Design; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Structure-Activity Relationship; Tuberculosis, Multidrug-Resistant | 2013 |
Filling the pipeline - new drugs for an old disease.
Topics: Adamantane; Antitubercular Agents; Cyclic GMP-Dependent Protein Kinases; Diarylquinolines; Enzymes; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Humans; Molecular Targeted Therapy; Mycobacterium tuberculosis; Nitroimidazoles; Quantitative Structure-Activity Relationship | 2014 |
Tuberculosis: clinical trials and new drug regimens.
Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Novel drugs against tuberculosis: a clinician's perspective.
Topics: Adamantane; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarylquinolines; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Female; Follow-Up Studies; Humans; Male; Nitroimidazoles; Oxazoles; Oxazolidinones; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2015 |
Tuberculosis treatment and drug regimens.
Topics: Antitubercular Agents; China; Diarylquinolines; Humans; India; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; USSR | 2015 |
Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives.
Topics: Antitubercular Agents; Compassionate Use Trials; Diarylquinolines; Health Services Accessibility; Humans; Linezolid; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Vulnerable Populations | 2015 |
Bedaquiline and delamanid in tuberculosis.
Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Interactions; Drug Resistance, Bacterial; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2015 |
Management of drug resistantTB in patients with HIV co-infection.
Topics: Antitubercular Agents; Coinfection; Diarylquinolines; Disease Management; Extensively Drug-Resistant Tuberculosis; HIV Infections; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; World Health Organization | 2015 |
Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria.
Topics: Adamantane; Aminopyridines; Anti-Bacterial Agents; Azepines; Benzamides; Clinical Trials as Topic; Diarylquinolines; Drug Discovery; Ethylenediamines; Fluoroquinolones; Humans; Minocycline; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles; Piperazines; Spiro Compounds; Thiazines; Tigecycline; Uridine | 2016 |
Adverse effects of oral second-line antituberculosis drugs in children.
Topics: Age Factors; Antitubercular Agents; Child; Diarylquinolines; Dose-Response Relationship, Drug; HIV Infections; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2016 |
Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers.
Topics: Antitubercular Agents; Biomarkers; Clinical Trials as Topic; Coinfection; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; HIV Infections; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Practice Guidelines as Topic; Precision Medicine | 2017 |
Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations.
Topics: Aged; Animals; Antitubercular Agents; Arrhythmias, Cardiac; Comorbidity; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diarylquinolines; Drug Interactions; Drug Monitoring; Humans; Hypoglycemic Agents; Middle Aged; Nitroimidazoles; Oxazoles; Polypharmacy; Risk Assessment; Risk Factors; Tuberculosis | 2016 |
Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2017 |
(Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis.
Topics: Administration, Oral; Antitubercular Agents; Clinical Trials, Phase III as Topic; Diarylquinolines; Evidence-Based Medicine; Humans; Linezolid; Needles; Nitroimidazoles; Oxazoles; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant | 2016 |
Current therapies for the treatment of multidrug-resistant tuberculosis in children in India.
Topics: Antitubercular Agents; Child; Diarylquinolines; Drug Administration Schedule; Humans; India; Microbial Sensitivity Tests; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2017 |
Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; World Health Organization | 2018 |
The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?
Topics: Antitubercular Agents; Diarylquinolines; Health Services Accessibility; Human Rights; Humans; Injections; Nitroimidazoles; Oxazoles; Patient-Centered Care; Tuberculosis, Multidrug-Resistant | 2017 |
Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches.
Topics: Antitubercular Agents; Computational Biology; Diarylquinolines; Drug Design; Extensively Drug-Resistant Tuberculosis; Humans; Models, Molecular; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Peptides; Tuberculosis; Tuberculosis, Multidrug-Resistant; World Health Organization | 2018 |
Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
Topics: Adolescent; Antitubercular Agents; Child; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
ADVANCES IN PHARMACOTHERAPY OF TUBERCULOSIS.
Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Humans; Nitroimidazoles; Oxazolidinones; Tuberculosis, Multidrug-Resistant | 2017 |
New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Repositioning; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles | 2018 |
Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Humans; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2018 |
Genetics and roadblocks of drug resistant tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Epistasis, Genetic; Humans; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Phylogeny; Tuberculosis, Multidrug-Resistant | 2019 |
Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Electrocardiography; Humans; Nitroimidazoles; Oxazoles; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2019 |
Development of new drug-regimens against multidrug-resistant tuberculosis.
Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Development; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Ethylenediamines; Humans; Isoniazid; Macrolides; Medication Adherence; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant | 2019 |
New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease.
Topics: Amikacin; Anti-Bacterial Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Liposomes; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Oxazoles | 2019 |
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Humans; Linezolid; Nitroimidazoles; Oxazoles; Periodicals as Topic; Pulmonary Medicine; Societies, Medical; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2019 |
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Linezolid; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pharmaceutical Preparations; Tuberculosis, Multidrug-Resistant | 2020 |
Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective.
Topics: Antitubercular Agents; Child; Clinical Trials as Topic; Diarylquinolines; Drug Therapy, Combination; Female; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pregnancy; Tuberculosis, Multidrug-Resistant | 2020 |
Evolution of newer regimens in TB from RNTCP to NTEP.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Nitroimidazoles; Oxazoles; Tuberculosis, Pulmonary | 2020 |
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin | 2022 |
Efficacy and Tolerability of Concomitant Use of Bedaquiline and Delamanid for Multidrug- and Extensively Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis.
Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2023 |
Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children.
Topics: Adult; Diarylquinolines; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2023 |
9 trial(s) available for azomycin and bedaquiline
| Article | Year |
|---|---|
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
Topics: Adult; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Prospective Studies; Pyrazinamide; Quinolines; Sputum; Tuberculosis, Pulmonary; Young Adult | 2012 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nitroimidazoles; Pyrazinamide; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2015 |
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
Topics: Antitubercular Agents; Computer Simulation; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Linezolid; Long QT Syndrome; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant | 2019 |
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Uganda | 2019 |
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Topics: Administration, Oral; Adolescent; Adult; Antitubercular Agents; Bacterial Load; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Humans; Intention to Treat Analysis; Linezolid; Male; Middle Aged; Mycobacterium tuberculosis; Nitroimidazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2020 |
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Nitroimidazoles; Oxazoles; Peru; Rifampin; South Africa; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2021 |
Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens.
Topics: Diarylquinolines; Electrocardiography; Heart Rate; Humans; Nitroimidazoles; Oxazoles | 2022 |
Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study
Topics: Adult; Antitubercular Agents; Diarylquinolines; Humans; Linezolid; Nitroimidazoles; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2022 |
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Topics: Aminoglycosides; Antitubercular Agents; Diarylquinolines; Fluoroquinolones; Humans; Linezolid; Nitroimidazoles; Rifampin; Risk Assessment; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
106 other study(ies) available for azomycin and bedaquiline
| Article | Year |
|---|---|
Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice.
Topics: Acetamides; Animals; Anti-Infective Agents; Aza Compounds; Diarylquinolines; Female; Fluoroquinolones; Leprosy; Linezolid; Mice; Moxifloxacin; Mycobacterium leprae; Nitroimidazoles; Oxazolidinones; Quinolines | 2006 |
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
Topics: Acetamides; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Foot; In Vitro Techniques; Linezolid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Nitroimidazoles; Oxazolidinones; Quinolines; Rifampin; Streptomycin; Survival Analysis; Time Factors | 2006 |
Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Female; Granuloma; Guinea Pigs; Hypoxia; Isoniazid; Lung; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Radiation-Sensitizing Agents; Rifampin; Spleen; Tuberculosis | 2007 |
[Some new antitubercular agents].
Topics: Acetamides; Antitubercular Agents; Diarylquinolines; Humans; Linezolid; Nitroimidazoles; Oxazoles; Oxazolidinones; Quinolines | 2008 |
The TB Alliance: overcoming challenges to chart the future course of TB drug development.
Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Diarylquinolines; Drug Evaluation, Preclinical; Fluoroquinolones; Humans; Models, Organizational; Moxifloxacin; Nitroimidazoles; Quinolines; Tuberculosis | 2011 |
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Secondary Prevention; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2011 |
Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide.
Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Monitoring; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Quinolines; Reproducibility of Results; Time Factors | 2012 |
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
Topics: Adamantane; Antitubercular Agents; Aza Compounds; Diarylquinolines; Drug Combinations; Drug Synergism; Ethambutol; Ethylenediamines; Fluoroquinolones; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Spiro Compounds; Thiazines; Thienamycins | 2012 |
Principles for designing future regimens for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Approval; Drug Design; Drug Resistance, Multiple, Bacterial; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2014 |
Improving the health of the tuberculosis drug pipeline.
Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Approval; Drug Discovery; Global Health; Humans; Nitroimidazoles; Oxazoles; Research Support as Topic; Tuberculosis | 2014 |
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Pyrazinamide; Random Allocation; Tuberculosis | 2015 |
Drug-resistance mechanisms and tuberculosis drugs.
Topics: Antitubercular Agents; Diarylquinolines; Drug Approval; Humans; Mutation; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2015 |
Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.
Topics: Antitubercular Agents; Diarylquinolines; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Reference Values; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2015 |
Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis.
Topics: Agar; Antitubercular Agents; Biological Assay; Charcoal; Colony Count, Microbial; Coloring Agents; Diarylquinolines; Fluorometry; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Xanthenes | 2015 |
Classification of antituberculosis drugs: a new proposal based on the most recent evidence.
Topics: Antitubercular Agents; Carbapenems; Clavulanic Acid; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Infectious Disease Medicine; Linezolid; Nitroimidazoles; Oxazoles; Practice Guidelines as Topic; Tuberculosis, Multidrug-Resistant; World Health Organization | 2015 |
Compassionate and optimum use of new tuberculosis drugs.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Health Services Accessibility; Humans; Male; Nitroimidazoles; Oxazoles; Pneumonectomy | 2015 |
Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
Topics: Antitubercular Agents; Computer Simulation; Cost-Benefit Analysis; Diarylquinolines; Drug Costs; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Germany; Humans; Markov Chains; Models, Economic; Nitroimidazoles; Oxazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant | 2015 |
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Load; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Linezolid; Lung; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Organophosphates; Oxazoles; Oxazolidinones; Pyrazinamide; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary | 2016 |
Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Male; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2015 |
Barriers to new drug development in respiratory disease.
Topics: Antitubercular Agents; Awards and Prizes; Diarylquinolines; Drug Discovery; Extensively Drug-Resistant Tuberculosis; Humans; Motivation; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2016 |
Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
Topics: Adult; Antitubercular Agents; Bacterial Load; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Eswatini; Female; Humans; Kenya; Logistic Models; Male; Middle Aged; Multivariate Analysis; Mycobacterium tuberculosis; Nitroimidazoles; Odds Ratio; Oxazoles; Patient Selection; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; USSR; Young Adult | 2016 |
Reciprocity and Ethical Tuberculosis Treatment and Control.
Topics: Antitubercular Agents; Beneficence; Communicable Disease Control; Congresses as Topic; Diarylquinolines; Directly Observed Therapy; Ethical Analysis; Ethical Theory; Global Health; Humans; Moral Obligations; Nitroimidazoles; Oxazoles; Patient Isolation; Personal Autonomy; Pharmacovigilance; Poverty; Public Health; Social Justice; Social Responsibility; Tuberculosis, Laryngeal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Virtues | 2016 |
Delamanid and Bedaquiline Resistance in Mycobacterium tuberculosis Ancestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee.
Topics: Adult; Antitubercular Agents; Beijing; Compassionate Use Trials; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Genotype; Humans; Male; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Refugees; Tibet | 2016 |
[New antitubercular agents are not where where we need them to be].
Topics: Antitubercular Agents; Developing Countries; Diarylquinolines; Health Services Accessibility; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2015 |
Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Approval; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2016 |
Global Introduction of New Multidrug-Resistant Tuberculosis Drugs-Balancing Regulation with Urgent Patient Needs.
Topics: Antitubercular Agents; Diarylquinolines; Drug Prescriptions; Drug Resistance, Bacterial; Drug Utilization; Humans; Legislation, Drug; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2016 |
First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Female; Humans; Nitroimidazoles; Oxazoles | 2016 |
Comparison of Effectiveness Between Delamanid and Bedaquiline Among Patients with Multidrug-Resistant Tuberculosis: A Markov Model Simulation Study.
Topics: Aged; Diarylquinolines; Female; Humans; Male; Middle Aged; Nitroimidazoles; Oxazoles; Quality-Adjusted Life Years; Tuberculosis, Multidrug-Resistant | 2016 |
A Bayesian response-adaptive trial in tuberculosis: The endTB trial.
Topics: Adaptive Clinical Trials as Topic; Algorithms; Antitubercular Agents; Bayes Theorem; Computer Simulation; Diarylquinolines; Humans; Nitroimidazoles; Oxazoles; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2017 |
Using bedaquiline and delamanid in combination and safely.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Global Health; Humans; Nitroimidazoles; Oxazoles; Tuberculosis | 2016 |
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2016 |
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2016 |
Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; World Health Organization | 2017 |
Estimated generic prices for novel treatments for drug-resistant tuberculosis.
Topics: Algorithms; Antitubercular Agents; Commerce; Diarylquinolines; Drug Costs; Drugs, Generic; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2017 |
Easier cure for resistant TB.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Baltimore; Clinical Trials as Topic; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Mycobacterium tuberculosis; Nitroimidazoles; South Africa; Sputum; Treatment Outcome | 2017 |
India plans to expand access to new tuberculosis drug.
Topics: Antitubercular Agents; Diarylquinolines; Health Services Accessibility; Humans; India; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2017 |
TB Alliance regimen development for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant | 2016 |
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Topics: Adult; Antitubercular Agents; Clinical Protocols; Clinical Trials as Topic; Cost-Benefit Analysis; Diarylquinolines; Drug Costs; Drug Therapy, Combination; Female; Germany; Humans; Linezolid; Male; Nitroimidazoles; Observational Studies as Topic; Oxazoles; Quality-Adjusted Life Years; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2017 |
Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Pulmonary | 2017 |
Topics: Antitubercular Agents; Beijing; China; Clofazimine; Diarylquinolines; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles | 2017 |
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Humans; Male; Nitroimidazoles; Oxazoles; Tuberculosis, Pulmonary; Young Adult | 2017 |
Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Azithromycin; Child; Clarithromycin; Clofazimine; Diarylquinolines; Female; Fluoroquinolones; Follow-Up Studies; Humans; Lost to Follow-Up; Macrolides; Male; Middle Aged; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult | 2017 |
Bedaquiline or delamanid for rifampin-resistant tuberculosis?
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Bacterial; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Rifampin; Tuberculosis, Multidrug-Resistant | 2017 |
Incorporating social justice and stigma in cost-effectiveness analysis: drug-resistant tuberculosis treatment.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Decision Trees; Diarylquinolines; Humans; Models, Theoretical; Nitroimidazoles; Oxazoles; Social Justice; Social Stigma; South Africa; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2017 |
World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied?
Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Humans; Nitroimidazoles; Oxazoles; Practice Guidelines as Topic; Tuberculosis, Multidrug-Resistant; World Health Organization | 2017 |
Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia.
Topics: Adult; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; France; Humans; Latvia; Male; Nitroimidazoles; Oxazoles; Patient Safety; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2018 |
Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.
Topics: Adult; Antitubercular Agents; Colistin; Diarylquinolines; Drug Synergism; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Male; Medication Adherence; Mycobacterium tuberculosis; Netherlands; Nitroimidazoles; Oxazoles; Patient Isolation; Phenotype; Trimethoprim, Sulfamethoxazole Drug Combination; United Kingdom | 2018 |
Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis.
Topics: Armenia; Diarylquinolines; Humans; India; Nitroimidazoles; Oxazoles; Retrospective Studies; South Africa; Tuberculosis, Multidrug-Resistant | 2018 |
Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Topics: Adult; Antitubercular Agents; Armenia; Arrhythmias, Cardiac; Cohort Studies; Diarylquinolines; Drug Therapy, Combination; HIV Infections; Humans; India; Nitroimidazoles; Oxazoles; Retrospective Studies; South Africa; Tuberculosis, Multidrug-Resistant | 2018 |
Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
Topics: Adult; Antitubercular Agents; Cohort Studies; Diarylquinolines; Drug Administration Schedule; Female; Geography; Humans; Male; Middle Aged; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Republic of Korea; Tuberculosis, Multidrug-Resistant; World Health Organization | 2018 |
Using new TB tools: global rhetoric and ground reality.
Topics: Diarylquinolines; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2018 |
Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Humans; Internationality; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2018 |
The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis.
Topics: Antitubercular Agents; Communicable Disease Control; Databases, Factual; Diarylquinolines; Humans; Infectious Disease Medicine; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Patient Safety; Public Health; Rifampin; Tuberculosis, Multidrug-Resistant; World Health Organization | 2018 |
Will regulatory issues continue to be a major barrier to access to bedaquiline and delamanid?
Topics: Antitubercular Agents; Diarylquinolines; Diffusion of Innovation; Drug and Narcotic Control; Drug Approval; Global Health; Health Services Accessibility; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2018 |
QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study.
Topics: Antitubercular Agents; Cardiotoxicity; Cross-Sectional Studies; Diarylquinolines; Electrocardiography; Europe; Humans; Internationality; Long QT Syndrome; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2018 |
Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Humans; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Reproducibility of Results; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2018 |
Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study.
Topics: Adolescent; Adult; Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Liberation; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Nitroimidazoles; Oxazoles; Proof of Concept Study; Rifampin; Treatment Outcome; Young Adult | 2018 |
Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Topics: Antitubercular Agents; Diarylquinolines; DNA Mutational Analysis; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Republic of Korea; Tuberculosis, Multidrug-Resistant | 2018 |
Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China.
Topics: Adult; Cost-Benefit Analysis; Diarylquinolines; Follow-Up Studies; Hong Kong; Humans; Middle Aged; Monte Carlo Method; Nitroimidazoles; Oxazoles; Quality-Adjusted Life Years; Retrospective Studies; Socioeconomic Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2019 |
Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Compassionate Use Trials; Diarylquinolines; Drug Therapy, Combination; Female; HIV Infections; Humans; Internationality; Male; Middle Aged; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Young Adult | 2019 |
'Those who cannot remember the past are condemned to repeat it': Drug-susceptibility testing for bedaquiline and delamanid.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Bacterial; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles | 2019 |
Journey of tuberculosis control in India.
Topics: Antitubercular Agents; Diarylquinolines; Directly Observed Therapy; Goals; History, 20th Century; History, 21st Century; Humans; India; National Health Programs; Nitroimidazoles; Oxazoles; Practice Guidelines as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2019 |
Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis.
Topics: Adult; Cardiotoxicity; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Electrocardiography; Female; Humans; Imipenem; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Salvage Therapy; Sputum; Survival Rate; Tuberculosis, Multidrug-Resistant; Young Adult | 2019 |
The STREAM trial: missed opportunities and lessons for future clinical trials.
Topics: Antitubercular Agents; Deafness; Diarylquinolines; Humans; Nitroimidazoles; Oxazoles; Randomized Controlled Trials as Topic; Research Design; Time Factors; Tuberculosis, Multidrug-Resistant | 2019 |
Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Bacterial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Treatment Outcome | 2019 |
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Male; Nitroimidazoles; Oxazoles; Pilot Projects; Tuberculosis; Tuberculosis, Multidrug-Resistant; World Health Organization | 2019 |
Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
Topics: Antitubercular Agents; Cohort Studies; Diarylquinolines; Drug Therapy, Combination; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2019 |
Acquired Drug Resistance: Recognizing the Potential of Repurposed Drugs.
Topics: Diarylquinolines; Drug Resistance; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles | 2019 |
Topics: Anti-Bacterial Agents; Antitubercular Agents; Diarylquinolines; Humans; Macrolides; Microbial Sensitivity Tests; Mycobacterium abscessus; Mycobacterium avium Complex; Mycobacterium Infections, Nontuberculous; Mycobacterium kansasii; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles | 2019 |
In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Drug Synergism; Extensively Drug-Resistant Tuberculosis; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Tuberculosis, Multidrug-Resistant; Xanthenes | 2019 |
The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Nitroimidazoles; Observational Studies as Topic; Oxazoles; Prospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2019 |
Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Humans; Markov Chains; Nitroimidazoles; Prevalence; Pyrazinamide; Rifampin; South Africa; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2019 |
BPaL approved for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Approval; Drug Therapy, Combination; Humans; Linezolid; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2019 |
A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Humans; Nitroimidazoles; Oxazoles; Prospective Studies; Tuberculosis, Multidrug-Resistant | 2020 |
Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Female; Georgia; Humans; Male; Nitroimidazoles; Oxazoles; Prospective Studies; Tuberculosis, Multidrug-Resistant | 2020 |
Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative?
Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 2019 |
Bedaquiline and Delamanid in Children With XDR Tuberculosis: What is prolonged QTc?
Topics: Adolescent; Antitubercular Agents; Child; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Female; Humans; Male; Nitroimidazoles; Oxazoles; Sputum; Tomography, X-Ray Computed | 2020 |
Tuberculosis treatment: one-shot approach or cascade of regimens?
Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 2020 |
Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea.
Topics: Age Factors; Aged; Body Mass Index; Diarylquinolines; Drug Resistance, Bacterial; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Nitroimidazoles; Oxazoles; Republic of Korea; Retrospective Studies; Risk Factors; Safety; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary | 2020 |
Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid.
Topics: Adult; Aged; Antitubercular Agents; Diarylquinolines; Female; Humans; Male; Middle Aged; Nitroimidazoles; Oxazoles; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2020 |
Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Linezolid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2020 |
Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2021 |
Operational Research on the Treatment of Drug-Resistant Tuberculosis: Exciting Results That Need to Be Protected.
Topics: Diarylquinolines; Humans; Nitroimidazoles; Operations Research; Oxazoles; Prospective Studies; Tuberculosis, Multidrug-Resistant | 2021 |
Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains.
Topics: Antitubercular Agents; Diarylquinolines; Genomics; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2020 |
One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Female; Humans; India; Nitroimidazoles; Oxazoles; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2021 |
Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea.
Topics: Antitubercular Agents; Cohort Studies; Diarylquinolines; Fluoroquinolones; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Republic of Korea; Tuberculosis, Multidrug-Resistant | 2021 |
Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Nitroimidazoles; Oxazoles; Prospective Studies; Tuberculosis, Multidrug-Resistant | 2021 |
Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19.
Topics: Adolescent; Antitubercular Agents; Child; Cohort Studies; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Female; Humans; Male; Nitroimidazoles; Oxazoles; Republic of Belarus | 2021 |
Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Linezolid; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Recurrence; Tuberculosis | 2021 |
Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.
Topics: Adolescent; Ambulatory Care Facilities; Antitubercular Agents; Child; Child, Preschool; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Female; Humans; India; Infant; Infant, Newborn; Male; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2021 |
Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis.
Topics: Diarylquinolines; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2021 |
Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid.
Topics: Antitubercular Agents; Cohort Studies; Diarylquinolines; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2021 |
Outcomes of Children Born to Pregnant Women With Drug-resistant Tuberculosis Treated With Novel Drugs in Khayelitsha, South Africa: A Report of Five Patients.
Topics: Adult; Antitubercular Agents; Child Health; Child, Preschool; Diarylquinolines; Female; Humans; Infant; Infant Health; Linezolid; Nitroimidazoles; Oxazoles; Pregnancy; Pregnancy Outcome; Pregnant Women; South Africa; Tuberculosis, Multidrug-Resistant; Young Adult | 2021 |
Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China.
Topics: China; Diarylquinolines; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Phylogeny; Prevalence; Retrospective Studies | 2021 |
Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Humans; Mutation; Mycobacterium smegmatis; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing | 2021 |
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Georgia; Humans; Linezolid; Nitroimidazoles; Philippines; South Africa; Tuberculosis, Multidrug-Resistant | 2021 |
Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid.
Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Granuloma; Humans; Linezolid; Nitroimidazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2021 |
Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2022 |
Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Nitroimidazoles | 2022 |
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort.
Topics: Antitubercular Agents; Diarylquinolines; Electrolytes; Humans; Linezolid; Nitroimidazoles; Oxazoles; Prospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2022 |
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
Topics: Antitubercular Agents; Clofazimine; Cohort Studies; Diarylquinolines; Electrolytes; Fluoroquinolones; Humans; Linezolid; Nitroimidazoles; Oxazoles; Prospective Studies; Rifampin; Tuberculosis, Multidrug-Resistant | 2022 |
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifabutin; Tuberculosis | 2022 |
Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline.
Topics: Adult; Albumins; Antitubercular Agents; Diarylquinolines; HIV Infections; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2022 |
Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide.
Topics: Antitubercular Agents; Diarylquinolines; Humans; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2022 |
Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic Modeling.
Topics: Animals; Antitubercular Agents; Humans; Lung; Mice; Nitroimidazoles; Pyrazinamide; Tuberculosis | 2023 |
Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB.
Topics: Antitubercular Agents; Diarylquinolines; Female; Humans; Middle Aged; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2023 |